RNAceuticals is developing a disruptive category of medicines based on self-amplifying RNA or SAR that promises better medicines across the spectrum of human diseases. Acting as cellular software, SAR medicines instruct a patient’s own cells to make proteins that prevent, treat and cure disease. SAR medicines have the potential to be more effective, longer lasting, safer and more affordable than the protein-based medicines made by cell culture today.
Although the idea of using RNA to function as a medicine is not new, putting it into practice has required new technologies to effectively deliver RNA to cells, and, for some uses, reduce anti-RNA defenses. The company calls its combination of SAR and delivery technologies “VECTORNA™”. Distinguishing features of VECTORNA compared to competing mRNA technologies include lower effective doses and longer therapeutic windows.
We are collaborating with University of California, Irvine scientists who have developed proprietary, synthetic nanoparticle formulations to effectively deliver SAR. Our product pipeline is focused on immunotherapeutic proteins, which are the subjects of collaborations with the National Institutes of Health (NIH) and the U.S. Army (Army) and plan to deliver candidates for evaluation by the NIH and Army in the second quarter of 2019.
Serial biotech entrepreneur Franklin Volvovitz and pharma industry veteran George Mark, III, Ph.D. lead RNAceuticals. Mr. Volvovitz previously founded Protein Sciences Corporation (PSC). Under his leadership the first and only FDA licensed, recombinant influenza vaccine, Flublok, was invented and brought to clinical trials. Sanofi purchased PSC for $650 million plus milestone payments in late 2017. Dr. Mark has led research teams at Merck and Celldex, which advanced a broad range of vaccine and antibody candidates including Merck’s Gardasil and RotaTeq vaccines from early development to clinical trials.